Form 4 for OPRX OptimizeRx Corp
Accepted 2023-11-03 00:00:00 ET · period of report 2023-11-01 · accession 0001628280-23-036588 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-03 | 2023-11-01 | OPRX | Greco Theresa | Chief Commercial Off | A - Grant | $0.00 | +18.5K | 37.0K | +100% | $0 |
| D | 2023-11-03 | 2023-11-01 | OPRX | Greco Theresa | Chief Commercial Off | A - Grant | $0.00 | +35.8K | 35.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-01 | A | A | 18,519 | $0.00 | 37,038 | D | — | — | (F1) Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on November 1, 2024, which is the first anniversary of the date of grant. |
| 2 | Derivative | Stock Option | 2023-11-01 | A | A | 35,758 | $0.00 | 35,758 | D | $8.10 · — to 2028-11-01 | 35,758 Common Stock | (F2) The stock option vests in three equal annual installments beginning November 1, 2024, the first anniversary of the grant date. |